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ABSTRACT
A series of 4-(2-(4-substituted phenyl)-4-oxoquinazolin-3(4H)-yl)-N-(2-(4-fluorophenyl)-4-oxo-5-
(arylidene)thiazolidin-3-yl) benzamides (VIa-n) have been synthesized by condensation of N-(2-(4-
fluorophenyl)-4-oxothiazolidin-3-yl)-4-(4-oxo-2-(4-substituted phenyl)quinazolin-3(4H)-yl)benzamides 
(Va-b) with various aryl/heteroaryl aldehydes using conventional methodology. All compounds were 
screened for their in vitro anticancer activity against the human breast cancer cell lines (MCF-7), human 
lung cancer cell lines (A549) using MTT assay method and doxorubicin is used as standard drug. Com-
pound VId, VIk and VIn showed high potency against A549 cell lines with IC50 values 0.035±0.002 µM, 
0.031±0.002 µM and 0.030±0.002 µM respectively compared to 0.023±0.002 µM showed by the standard. 
However, highest activity against MCF-7 cell lines was exhibited by Va, Vb, VIk and VIn with IC50 values 
between 0.040 - 0.050 µM. All the remaining compounds showed moderate anticancer activity against 
both the MCF-7 and A549 cell lines. To understand the interactions with active binding site of receptor, 
molecular docking study was also performed.
Keywords: Quinazolin-4(3H)-one; Thiazolidin-4-one; Anticancer activity; Molecular docking.
RESUMEN
Una serie de 2- (4-sustituido fenil) -4-oxoquinazolin-3 (4H) -il) -N- (2- (4-fluorofenil) -4-oxo-5- (arilide-
no) tiazolidin-3-ilo) benzamidas (VIa-n) han sido sintetizadas por condensación de N- (2- (4-fluorofenil) 
-4-oxotiazolidin-3-il) -4- (4-oxo-2- (4-fenil sustituido) quinazolin-3 (4H) -il) benzamidas (Va-b) con diver-
sos aldehídos de arilo / heteroarilo usando metodología convencional. Todos los compuestos se cribaron 
para su actividad anticancerosa in vitro contra las líneas celulares de cáncer de mama humano (MCF-7), 
líneas celulares de cáncer de pulmón humano (A549) usando el método de ensayo MTT y se usa doxor-
rubicina como fármaco estándar. El compuesto VId, VIk y VIn mostraron alta potencia contra las líneas 
celulares A549 con valores IC50 de 0.035 ± 0.002 μM, 0.031 ± 0.002 μM y 0.030 ± 0.002 μM, respectiva-
mente, en comparación con 0.023 ± 0.002 μM mostrada por el estándar. Sin embargo, la actividad más 
alta contra líneas celulares MCF-7 fue exhibida por Va, Vb, VIk y VIn con valores de CI50 entre 0.040 
- 0.050 μM. Todos los compuestos restantes mostraron una actividad anticancerígena moderada contra 
las líneas celulares MCF-7 y A549. Para comprender las interacciones con el sitio de unión activa del 
receptor, también se realizó el estudio de acoplamiento molecular.
Palabras clave: Quinazolin-4 (3H) -ona; Thiazolidin-4-one; Actividad anticancerosa; Atraque molecular.
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INTRODUCTION
Cancer is a disease of worldwide importance. Its incidence 
in the developed countries is increasing, and it occupies 
the second rank in the order of death causes1. Genotoxic-
ity and cytotoxicity of anti-cancer drugs to the normal tis-
sues is major problems in cancer therapy. However, can-
cer research always requires the discovery of new drugs 
that can kill the cancer cells or stop the growth of cancer 
cells more specifically and overcome the limitation of tox-
icity to normal tissue leading to many undesirable side 
effects2. Quinazoline derivatives have been identified as a 
new class of cancer chemotherapeutic agents with signif-
icant therapeutic efficacy against solid tumors3. Hybrid 
anti-cancer agents, which combine quinazoline and phe-
nylquinoxaline moieties in one were reported and found to 
possess enhanced cytotoxicity and specificity4. 4-Oxo-thi-
azolidine derivatives have occupied a unique place in the 
field of medicinal chemistry due to a wide range of bio-
logical activities5. 4-Thiazolidinones have been reported to 
inhibit tumor cell proliferation through inducing cell cycle 
arrest6. Recently 2-phenyl-(4-oxothiazolidin-3-yl)-quinazo-
lin-4(3H)-one derivatives were found to possess potent ac-
tivity against MCF-7 and HepG2 cell lines7. In our present 
study, we have designed and synthesized a new series of 
quinazolin-4(3H)-one and 4-thiazolidinone hybrid mole-
cules as new anticancer agents with improved activity pro-
file. In the process the C2 position of quinazolin-4(3H)-one 
was attached with substituted phenyl ring and the C5 po-
sition of 4-thiazolidinone substituted with various aryl and 
heteroaryl ring systems (Figure: 1).
Figure 1: General structure of the synthesized compounds (VIa-n).
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Scheme 1: Synthetic route of the final compounds (Via-n). (a) Pyridine; stirring at 15-20 ºC, 1-2 hrs; (b) 
Ethyl 4-amino benzoate, heated on an oil bath at 180-200 ºC for 25 min; (c) NH2-NH2.H2O, methanol, 3 
hrs reflux; (d) Methanol, glacial acetic acid, 5 hrs reflux; (e) HSCH2COOH, 1,4-dioxane, 6 hrs reflux; (f) 
Ar-CHO, 1,4-dioxane, glacial acetic acid, 8 hrs reflux.
EXPERIMENTAL
All the chemicals and solvents were supplied by Sig-
ma-Aldrich Pvt Ltd. The column chromatography was 
performed on silica gel 60-100 (Merk) for purification of 
the compounds using ethylacetate: hexane and chloro-
form: methanol in different ratios as mobile phase. Melting 
points were determined using MEL TEMP electrothermal 
apparatus. IR spectrum was acquired on Perkin Elmer 
FT-IR spectrometer. Both 1H-NMR and 13C-NMR spectra 
of the compounds were taken on Bruker Avance-II 400 
NMR Spectrometer operating at 400 MHz and 100 MHz 
respectively at IICT, Hyderabad and Andhra University, 
Vishakapatnam. Mass spectra were recorded at IICT, Hy-
derabad. The elemental analysis was carried out using El-
ementar Vario Micro Cube at UCPSc, Kakatiya University, 
Warangal. 
Chemistry
Preparation of intermediate compounds 2-(4-substituted 
phenyl)benzo[d]1,3-oxazin-4-ones Ia-b were carried out ac-
cording to the literature method8. 
Preparation of ethyl 4-[2-(4-sustituted phenyl)-4-oxo-
quinazolin-3(4H)-yl] benzoate (IIa-b)
A mixture of compound (Ia-b) (0.01 mol) and ethyl 4-amino 
benzoate (0.012 mol) were fused at a temperature of 180-
200oC for 25 min. After cooling, the reaction mixture was 
treated with methanol carefully portion wise the solid was 
separated by filtration, dried and recrystallized from etha-
nol to give the corresponding derivatives IIa & IIb. [(IIa, R 
= CH3; C24H20N2O3; % Yield 63, M.P. 162-166oC); (IIb, R = 
Cl; C23H17ClN2O3; % Yield 57, M.P. 186-190oC)].
Preparation of 4-[2-(4-substituted phenyl)-4-oxoquina-
zolin-3(4H)-yl] benzohydrazide (IIIa-b)
A mixture of 4-[2-(4-substituted phenyl)-4-oxoquinazo-
lin-3(4H)-yl] benzoates (IIa-b) (0.01 mol) and excess of hy-
drazine hydrate (99%, 0.015 mol) in methanol (20 ml) were 
transferred to a round bottom flask and refluxed for 3 h. 
After the reaction was completed, the reaction mixture was 
poured into crushed ice to afford dark brown precipitates. 
These precipitates were collected by filtration and washed 
with cold water. The resulting solids were recrystallized 
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from ethanol (99%) to give the corresponding hydrazides 
(IIIa & IIIb). [(IIIa, R = CH3; C22H18N4O2; % Yield 75, M.P. 
182-186oC); (IIIb, R = Cl; C21H15ClN4O2; % Yield 68, M.P. 
204-208oC)]. 
Preparation of N-(4-fluorobenzylidene)-4-(4-oxo-2-
(4-substituted phenyl)-quinazolin-3(4H)-yl) benzohy-
drazide (IVa-b) 
The compounds IVa & IVb were prepared by refluxing 
4-[2-(4-substituted phenyl)-4-oxoquinazolin-3(4H)-yl)] 
benzohydrazides (IIIa-b; 0.01 mol) and 4-fluorobenzal-
dehyde (0.012 mol) in methanol (30 ml) containing small 
amount of glacial acetic acid for 5 h. After the reaction was 
completed, the Schiff bases (IVa-b) were precipitated out. 
The precipitate was collected by filtration. The resulting 
solids were recrystallized from methanol. [(IVa, R = CH3; 
C29H21FN4O2; % Yield 58, M.P. 224-228oC; IVb, R = Cl; 
C28H18ClFN4O2; % Yield 53, M.P. 240-244oC)].
Preparation of N-(2-(4-fluorophenyl)-4-oxothiazoli-
din-3-yl)-4-(4-oxo-2-(4-substituted phenyl)-quinazolin 
quinazolin-3(4H)-yl)benzamide (Va-b)
The synthesis of compounds (Va-b) was achieved by re-
fluxing N-(4-fluorobenzylidene)-4-(4-oxo-2-(4-substituted 
phenyl)-quinazolin-3(4H)-yl) benzo hydrazides (IVa-b; 0.01 
mol) and thioglycolic acid in 1,4 dioxan (20 ml) for 6 h. After 
the reaction was completed, the solution was poured into 
ice-cold aqueous solution of sodium bicarbonate to neutral-
ize unreacted thioglycolic acid. The yellow to brown solids 
separated were filtered and then washed with cold water. 
The resulting solids were recrystallized from ethanol. [(Va, 
R = CH3; C31H23FN4O3S; % Yield 76, M.P. 190-194oC); (Vb, R 
= Cl; C30H20ClFN4O3S; % Yield 65, M.P. 214-218oC)].
General procedure for synthesis of N-(5-(aryl)-2-(4-
fluorophenyl)-4-oxo thiazolidin-3-yl)-4-(4-oxo-2-(4-
substituted phenyl)-quinazolin-3(4H)-yl) benzamides 
(VIa–n).
A mixture of a solution of N-(2-(4-fluorophenyl)-4-oxothi-
azolidin-3-yl)-4-(4-oxo-2-(4-substituted phenyl)-quinazo-
lin-3(4H)-yl)benzamides (Va-b; 0.01 mol) and appropriate 
aryl aldehyde (0.01 mol) in 1,4 dioxane (20 ml) were added 
with a few drops of glacial acetic acid and refluxed for 8 
h. After the reaction was completed, the reaction mixture 
was poured into crushed ice to afford a precipitate. This 
was collected by filtration, and then washed with cold wa-
ter. The above procedure was applied to synthesize the 
arylidene derivatives VIa–n. All the derivatives were pu-
rified by column chromatography using mixture of ethyl 
acetate and hexane as mobile phase. (% Yield 54-71, M.P. 
190-252oC).
N-(2-(4-fluorophenyl)-4-oxo-5-(furan-2-ylmethylene)-
4-oxothiazolidin-3-yl)-4-(4-oxo-2-(p-tolyl) quinazo-
lin-3(4H)-yl) benzamide (VIa)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 2.28 (s, 3H, CH3); 
5.79 (s, 1H, -N-CH-S-); 7.37-7.48 (m, 2H, H); 7.53-7.89 (m, 
9H, H); 7.98-8.10 (m, 4H, H); 8.19-8.37 (m, 4H, Ar-H); 8.84 
(s, 1H, -C=CH-Ar); 9.12 (s, 1H, -CO-NH-). 13C – NMR: (100 
MHz; DMSO-d6) δ (ppm): 168.24, 166.46, 163.87, 162.35, 
157.87, 153.21, 147.82, 144.17, 139.78, 137.89, 137.50, 136.92, 
133.78, 130.06, 129.84, 127.69, 126.75, 125.47, 124.97, 120.85, 
116.12, 110.97, 108.74, 68.47, 19.43. IR: 3328.20 (N-H str); 
3108.50, 3086.40 (C-H Ar); 2932.70 (C-H Ali); 1709.80 (C=O 
str); 1674.70 (C=O str); 1567.40 (C=N str); 1241.10 (C-F str). 
Mass (m/z) (ESI-MS): [M+] 629. C, H, N: Calcd. C-68.78, 
H-4.01, N-8.91; Found C-69.10, H-4.33, N-9.23.
N-(2-(4-fluorophenyl)-4-oxo-5-(thiophen-2-ylmethyl-
ene)-4-oxothiazolidin-3-yl)-4-(4-oxo-2-(p-tolyl) quina-
zolin-3(4H)-yl) benzamide (VIb) 
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 2.23 (s, 3H, 
CH3); 5.88 (s, 1H, -N-CH-S-); 7.39-7.50 (m, 2H, Ar-H); 7.56-
7.873 (m, 10H, Ar-H); 7.98-8.26 (m, 7H, Ar-H); 8.84 (s, 1H, 
-C=CH); 9.11 (s, 1H, -CO-NH-). 13C – NMR: (100 MHz; DM-
SO-d6) δ (ppm): 166.27, 165.83, 162.17, 161.85, 157.74, 153.86, 
149.25, 144.38, 139.78, 137.89, 137.50, 136.92, 135.47, 134.06, 
131.64, 130.08, 129.65, 127.41, 126.35, 125.68, 124.16, 120.53, 
116.92, 112.37, 110.74, 69.23, 19.78. IR: 3304.83 (N-H str); 
309875, 3057.84 (C-H Ar); 2987.10 (C-H Ali); 1729.04 (C=O 
str); 1683.60 (C=O str); 1584.10 (C=N str); 1198.78 (C-F str). 
Mass (m/z) (ESI-MS): [M+] 645. C, H, N: Calcd. C-67.06, 
H-3.91, N-8.69; Found C-67.43, H-4.23, N-9.04.
N-(2-(4-fluorophenyl)-4-oxo-5-(pyridin-3-ylmethyl-
ene) thiazolidin-3-yl)-4-(4-oxo-2-(p-tolyl) quinazo-
lin-3(4H)-yl) benzamide (VIc)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 2.28 (s, 3H, CH3); 
5.90 (s, 1H, -N-CH-S-); 7.41-7.64 (m, 8H, Ar-H); 7.72-7.84 (m, 
2H, Ar-H); 7.94-8.12 (m, 4H, Ar-H); 8.19-8.28 (m, 2H, Ar-H); 
8.76-8.92 (m, 4H, -C=CH & Ar-H); 9.26 (d, 2H, J=8.528, -CO-
NH- & Ar-H). 13C – NMR: (100 MHz; DMSO-d6) δ (ppm): 
167.63, 164.75, 163.12, 160.09, 157.78, 150.09, 148.93, 147.81, 
141.07, 137.82, 136.43, 135.04, 132.65, 132.48, 130.07, 129.61, 
129.13, 127.28, 126.97, 125.65, 124.51, 124.03, 121.36, 117.18, 
68.31, 19.62. IR: 3312.63 (N-H str); 3112.44, 3097.32 (C-H 
Ar); 2962.46 (C-H Ali); 1712.64 (C=O str); 1682.09 (C=O str); 
1547.25 (C=N str); 1221.17 (C-F str). Mass (m/z) (ESI-MS): 
[M+] 640. C, H, N: Calcd. C-69.47, H-4.10, N-10.95; Found 
C-69.12, H-3.75, N-10.62.
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N-(5 -(4 -f luorobenzylidene)-2-(4 -f luorophenyl)- 4 -
oxothiazolidin-3-yl)-4-(4-oxo-2-(p-tolyl) quinazo-
lin-3(4H)-yl) benzamide (VId) 
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 2.40 (s, 3H, CH3); 
5.91 (s, 1H, -N-CH-S-); 7.22-7.32 (m, 3H, Ar-H); 7.48-7.56 (m, 
2H, Ar-H); 7.68-7.76 (m, 5H, Ar-H); 7.98-8.08 (m, 4H, Ar-H); 
8.30-8.38 (m, 3H, Ar-H); 8.61-8.72 (m, 3H, Ar-H); 8.87 (s, 1H, 
-C=CH); 9.26 (s, 1H, -CO-NH-). 13C – NMR: (100 MHz; DM-
SO-d6) δ (ppm): 166.07, 164.82, 160.35, 157.21, 149.27, 140.18, 
137.89, 134.12, 130.81, 129.84, 127.53, 126.96, 126.07, 124.85, 
116.74, 72.48, 20.08. IR: 3298.90 (N-H str); 3096.73, 3042.52 
(C-H Ar); 2943.89 (C-H Ali); 1720.36 (C=O str); 1671.37 
(C=O str); 1586.10 (C=N str); 1198.95 (C-F str). Mass (m/z) 
(ESI-MS): [M+] 657. C, H, N: Calcd. C-69.50, H-3.99, N-8.53; 
Found C-69.18, H-3.67, N-8.21. 
N-(5-(2-chlorobenzylidene)-2-(4 -fluorophenyl)- 4 -
oxothiazolidin-3-yl)-4-(4-oxo-2-(p-tolyl) quinazo-
lin-3(4H)-yl) benzamide (VIe)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 2.39 (s, 3H, CH3); 
5.81 (s, 1H, -N-CH-S-); 7.27-7.33 (m, 2H, Ar-H); 7.38-7.47 (m, 
6H, Ar-H); 7.63-7.72 (m, 3H, Ar-H); 7.78-7.85 (m, 3H, Ar-
H); 7.92-7.99 (m, 4H, Ar-H); 8.42-8.49 (m, 2H, Ar-H); 8.78 (s, 
1H, -C=CH); 9.21 (s, 1H, -CO-NH-). 13C – NMR: (100 MHz; 
DMSO-d6) δ (ppm): 165.13, 164.28, 161.39, 156.84, 149.27, 
140.13, 137.46, 134.92, 133.27, 131.48, 130.12, 129.85, 129.36, 
127.83, 126.75, 125.87, 125.26, 120.96, 115.82, 69.24, 19.82. IR: 
3294.82 (N-H str); 3100.12, 3053.64 (C-H Ar); 2964.17 (C-H 
Ali); 1707.68 (C=O str); 1644.83 (C=O str); 1589.75 (C=N 
str); 1209.78 (C-F str). Mass (m/z) (ESI-MS): [M+] 673. C, H, 
N: Calcd. C-67.80, H-3.89, N-8.32; Found C-68.10, H-4.22, 
N-8.63. 
N-(5-(4 -chlorobenzylidene)-2-(4 -f luorophenyl)- 4 -
oxothiazolidin-3-yl)-4-(4-oxo-2-(p-tolyl) quinazo-
lin-3(4H)-yl) benzamide (VIf) 
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 2.26 (s, 3H, CH3); 
5.87 (s, 1H, -N-CH-S-); 7.38-7.62 (m, 5H, Ar-H); 7.79-8.10 
(m, 8H, Ar-H); 8.17-8.33 (m, 4H, Ar- H); 8.43-8.60 (m, 3H, 
Ar-H); 8.90 (s, 1H, -C=CH); 9.26 (s, 1H, -CO-NH-). 13C – 
NMR: (100 MHz; DMSO-d6) δ (ppm): 165.13, 164.28, 161.39, 
156.84, 149.27, 140.13, 137.46, 134.92, 133.67, 130.97, 130.04, 
129.85, 129.36, 127.83, 126.75, 125.87, 125.26, 120.96, 115.82, 
69.24, 19.82. IR: 3289.12 (N-H str); 3111.45, 3097.24 (C-H 
Ar); 2978.10 (C-H Ali); 1718.05 (C=O str); 1665.85 (C=O str); 
1578.42 (C=N str); 1208.63 (C-F str). Mass (m/z) (ESI-MS): 
[M+] 673. C, H, N: Calcd. C-67.80, H-3.89, N-8.32; Found 
C-68.14, H-4.23, N-8.64.
N-(2-(4-fluorophenyl)-5-(4-methoxybenzylidene)-4-
oxothiazolidin-3-yl)-4-(4-oxo-2-(p-tolyl) quinazo-
lin-3(4H)-yl) benzamide (VIg)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 2.18 (s, 3H, CH3); 
3.90 (s, 3H, OCH3); 5.88 (s, 1H, -N-CH-S-); 7.07-7.22 (m, 4H, 
Ar-H); 7.25-7.36 (m, 2H, Ar-H); 7.43-7.68 (m, 6H, Ar-H); 
7.73-7.89 (m, 3H, Ar-H); 7.92-8.07 (m, 3H, Ar-H); 8.26-8.40 
(m, 2H, Ar-H); 8.82 (s, 1H, -C=CH); 9.24 (s, 1H, -CO-NH-). 
13C – NMR: (100 MHz; DMSO-d6) δ (ppm): 165.13, 164.28, 
161.39, 156.84, 149.27, 140.13, 137.46, 134.92, 133.27, 131.48, 
130.12, 129.85, 129.36, 127.83, 126.75, 125.87, 125.26, 120.96, 
115.82, 69.24, 19.82. IR: 3278.20 (N-H str); 3104.50, 3082.40 
(C-H Ar); 2923.70 (C-H Ali); 1711.45 (C=O str); 1680.35 
(C=O str); 1574.56 (C=N str); 1217.24 (C-F str). Mass (m/z) 
(ESI-MS): [M+] 669. C, H, N: Calcd. C-70.04, H-4.37, N-8.38; 
Found C-69.65, H-4.06, N-8.02.
4-(2-(4-chlorophenyl)-4-oxo quinazolin-3(4H)-yl)-N-
(2-(4-fluorophenyl)-4-oxo-5-(furan-2-ylmethylene) thi-
azolidin-3-yl) benzamide (VIh)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 5.79 (s, 1H, 
-N-CH-S-); 7.56-7.83 (m, 11H, Ar-H); 7.98-8.14 (m, 3H, Ar-
H); 8.20-8.49 (m, 5H, Ar-H); 8.83 (s, 1H, -C=CH); 9.11 (s, 
1H, -CO-NH-). 13C – NMR: (100 MHz; DMSO-d6) δ (ppm): 
165.37, 164.10, 161.28, 157.06, 152.48, 149.24, 144.60, 138.18, 
136.83, 135.46, 133.81, 129.56, 128.83, 127.63, 126.42, 125.06, 
121.75, 116.54, 113.68, 110.35, 72.17. IR: 3386.75 (N-H str); 
3189.60, 3046.32 (C-H Ar); 2934.61 (C-H Ali); 1708.13 (C=O 
str); 1676.02 (C=O str); 1591.52 (C=N str); 1175.18 (C-F str); 
723.92 (C-Cl str). Mass (m/z) (ESI-MS): [M+] 649. C, H, N: 
Calcd. C-64.76, H-3.42, N-8.63; Found C-64.42, H-3.10, 
N-8.31.
4-(2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-N-
(2-(4-fluorophenyl)-4-oxo-5-(thiophen -2-ylmethylene) 
thiazolidin-3-yl) benzamide (VIi)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 5.79 (s, 1H, 
-N-CH-S-); 7.48-7.61 (m, 3H, Ar-H); 7.67-7.86 (m, 8H, Ar-
H); 7.98-8.24 (m, 3H, Ar-H); 8.20-8.49 (m, 5H, Ar-H); 8.43-
8.56 (m, 2H, Ar-H); 8.83 (s, 1H, -C=CH); 9.11 (s, 1H, -CO-
NH-). 13C – NMR: (100 MHz; DMSO-d6) δ (ppm): 165.42, 
163.92, 161.15, 157.23, 148.94, 138.05, 136.70, 135.68, 133.76, 
131.28, 130.65, 129.86, 128.73, 127.52, 126.75, 125.16, 121.28, 
116.42, 71.85. IR: 3316.54 (N-H str); 3127.43, 3098.12 (C-H 
Ar); 2914.16 (C-H Ali); 1718.23 (C=O str); 1686.42 (C=O str); 
1545.12 (C=N str); 1185.34 (C-F str); 726.21 (C-Cl str). Mass 
(m/z) (ESI-MS): [M+] 665. C, H, N: Calcd. C-63.20, H-3.33, 
N-8.42; Found C-63.57, H-3.70, N-8.79.
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4-(2-(4-chlorophenyl) -4-oxo quinazolin-3(4H)-yl)-N-
(2-(4-fluorophenyl)-4-oxo-5-(pyridin-3-ylmethylene) 
thiazolidin-3-yl) benzamide (VIj) 
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 5.95 (s, 1H, 
-N-CH-S-); 7.42-7.59 (m, 3H, Ar-H); 7.69-7.83 (m, 3H, Ar-H); 
7.92-8.11 (m, 4H, Ar-H); 8.18-8.30 (m, 3H, Ar-H); 8.43-8.62 
(m, 3H, Ar-H); 8.78-8.90 (m, 3H, Ar-H); 9.04 (s, 1H, -C=CH); 
9.24 (s, 1H, -CO-NH-). 13C – NMR: (100 MHz; DMSO-d6) δ 
(ppm): 164.96, 163.84, 161.67, 160.43, 157.18, 151.60, 148.45, 
139.12, 137.42, 136.74, 134.45, 132.87, 130.67, 129.52, 128.90, 
127.45, 126.76, 125.38, 124.12, 121.60, 116.85, 72.10. IR: 
3296.72 (N-H str); 3142.35, 3042.12 (C-H Ar); 2914.67 (C-H 
Ali); 1711.43 (C=O str); 1684.32 (C=O str); 1568.72 (C=N 
str); 1186.23 (C-F str); 734.02 (C-Cl str). Mass (m/z) (ESI-MS): 
[M+] 660. C, H, N: Calcd. C-65.50, H-3.51, N-10.61; Found 
C-65.15, H-3.16, N-10.26.
4-(2-(4-chlorophenyl) - 4-oxoquinazolin-3(4H)-yl)-N-
(5-(4-fluoro benzylidene)-2-(4-fluoro phenyl)-4-oxo-
thiazolidin-3-yl) benzamide (VIk) 
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 5.87 (s, 1H, 
-N-CH-S-); 7.22-7.30 (m, 3H, Ar-H); 7.48-7.56 (m, 2H, Ar-
H); 7.67-7.86 (m, 5H, Ar-H); 7.98-8.06 (m, 4H, Ar-H); 8.28-
8.36 (m, 3H, Ar-H); 8.49-8.68 (m, 3H, Ar-H); 8.95 (s, 1H, 
-C=CH); 9.27 (s, 1H, -CO-NH-). 13C – NMR: (100 MHz; 
DMSO-d6) δ (ppm): 165.57, 164.42, 161.82, 160.35, 157.21, 
151.65, 149.27, 140.18, 137.89, 134.12, 130.81, 129.84, 127.53, 
126.96, 126.07, 124.85, 116.74, 72.48. IR: 3316.05 (N-H str); 
3118.40, 3074.32 (C-H Ar); 2925.46 (C-H Ali); 1712.18 (C=O 
str, amide); 1684.62 (C=O str); 1597.12 (C=N str); 1167.28 
(C-F str); 728.14 (C-Cl str). Mass (m/z) (ESI-MS): [M+] 677. 
C, H, N: Calcd. C-65.63, H-3.42, N-8.27; Found C-66.01, 
H-3.78, N-8.64. 
N-(5-(2-chlorobenzylidene)-2 - (4-fluorophenyl)-4-ox-
othiazolidin-3-yl)-4-(2-(4-chloro phenyl)-4-oxo quina-
zolin-3(4H)-yl) benzamide (VIl)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 5.82 (s, 1H, 
-N-CH-S-); 7.37-7.46 (m, 6H, Ar-H); 7.63-7.74 (m, 3H, Ar-H); 
7.80-7.85 (m, 3H, Ar-H); 7.92-8.00 (m, 4H, Ar-H); 8.23-8.30 
(m, 2H, Ar-H); 8.48-8.56 (m, 2H, Ar-H); 8.76 (s, 1H, -C=CH); 
9.21 (s, 1H, -CO-NH-). 13C – NMR: (100 MHz; DMSO-d6) δ 
(ppm): 165.74, 164.12, 162.32, 161.08, 157.25, 149.37, 139.18, 
137.89, 135.72, 133.56, 130.48, 130.48, 129.84, 128.90, 128.53, 
126.76, 125.20, 121.38, 116.85, 72.15. IR: 3307.62 (N-H str); 
3118.96, 3078.43 (C-H Ar); 2914.98 (C-H Ali); 1711.43 (C=O 
str); 1656.62 (C=O str); 1584.62 (C=N str); 1168.94 (C-F str); 
727.49 (C-Cl str). Mass (m/z) (ESI-MS): [M+] 694. C, H, N: 
Calcd. C-64.07, H-3.34, N-8.08; Found C-64.39, H-3.66, 
N-8.40. 
N-(5-(4-chlorobenzylidene)-2-(4-fluorophenyl)-4-oxo-
thiazolidin-3-yl)-4-(2-(4-chloro phenyl)-4-oxo quina-
zolin-3(4H)-yl) benzamide (VIm)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 5.86 (s, 1H, 
-N-CH-S-); 7.38-7.61 (m, 5H, Ar-H); 7.80-8.08 (m, 8H, Ar-
H); 8.16-8.32 (m, 4H, Ar-H); 8.40-8.62 (m, 3H, Ar-H); 8.90 (s, 
1H, -C=CH); 9.28 (s, 1H, -CO-NH-). 13C – NMR: (100 MHz; 
DMSO-d6) δ (ppm):165.75, 164.12, 161.08, 157.20, 149.62, 
139.86, 136.94, 135.78, 133.45, 131.40, 130.52, 129.76, 128.74, 
128.62, 126.47, 125.26, 121.30, 116.74, 71.83. IR: 3365.16 (N-H 
str); 3123.46, 3074.13 (C-H Ar); 2945.08 (C-H Ali); 1712.78 
(C=O str); 1672.61 (C=O str); 1584.52 (C=N str); 1178.07 
(C-F str); 728.19 (C-Cl str). Mass (m/z) (ESI-MS): [M+] 694. 
C, H, N: Calcd. C-64.07, H-3.34, N-8.08; Found C-64.39, 
H-3.66, N-8.40. 
4-(2-(4-chlorophenyl) - 4-oxoquinazolin-3(4H)-yl)-N-
(2-(4-fluorophenyl)-5(4-methoxy benzylidene)-4-oxo-
thiazolidin-3-yl) benzamide (VIn)
1H – NMR: (400 MHz; DMSO-d6) δ (ppm): 3.92 (s, 3H, Ar-
OCH3); 5.88 (s, 1H, -N-CH-S-); 7.16-7.32 (m, 4H, Ar-H); 
7.42-7.63 (m, 6H, Ar-H); 7.74-7.89 (m, 3H, Ar-H); 7.91-8.10 
(m, 3H, Ar-H); 8.22-8.40 (m, 4H, Ar-H); 8.82 (s, 1H, -C=CH); 
9.23 (s, 1H, -CO-NH-). 13C – NMR: (100 MHz; DMSO-d6) δ 
(ppm):165.80, 164.63, 162.17, 161.25, 160.10, 157.20, 149.62, 
138.56, 136.42, 135.78, 134.23, 131.84, 130.52, 129.26, 128.94, 
127.48, 126.67, 125.26, 124.53, 121.30, 116.74, 114.75, 71.90, 
56.47. IR: 3345.17 (N-H str); 3139.60, 3086.32 (C-H Ar); 
2932.61 (C-H Ali); 1712.84 (C=O str); 1694.02 (C=O str); 
1572.32 (C=N str); 1164.18 (C-F str); 724.92 (C-Cl str). Mass 
(m/z) (ESI-MS): [M+] 689. C, H, N: Calcd. C-66.23, H-3.80, 
N-8.13; Found. C-65.87, H-3.44, N-7.87.
Cell culture: The MCF-7 and A549 cell lines were main-
tained in culture with MEM medium, supplemented with 
10% FBS and the antibiotics penicillin/streptomycin (0.5 
mg/ml); in atmosphere of 5% CO2 and 95% air at 37ºC. 
Stock solutions of synthesized compounds were made in 
DMSO and kept in aliquots at -20ºC. For MTT assay, each 
test compound was weighed separately and dissolved in 
DMSO, made up the final concentration with media to 1 
mg/ml and the cells were treated with series of concentra-
tions from 10 to 100 μm. 
Molecular Docking 
Quinazolinone derivatives were reported to possess anti-
cancer activity by inhibiting target enzyme phosphoinos-
itide-3-OH kinase PI(3)K9, 10. Hence, in the present study, 
the titled compounds were docked on the PI(3)K to under-
stand the underlying mechanism. Docking studies were 
performed by Molegro Virtual Docker (MVD) program-
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mer11. The 3D coordinates of crystal structure of phospho-
inositide-3-OH kinase (PI(3)K) was obtained from protein 
data bank (PDB ID: 2WXQ) with resolution of 2.7 Å. The 
ligands were developed using Chem Draw Ultra 12.0. Li-
gands were further 3D optimized and saved in mol2 file 
format. MVD performs flexible ligand docking, so the opti-
mal geometry of the ligand will be determined during the 
docking. 
RESULTS 
Synthesis of Compounds
The titled compounds (VIa-n) were synthesized by the 
reported multi-step reaction protocol12, 13. The synthetic 
procedures were carried out as shown in Scheme-1. The 
starting materials (Ia-b) were prepared by the reaction of 
5-chloroanthranilic acid with substituted benzoyl chlo-
rides14, which were treated with ethyl-p-amino benzoate 
to give (IIa-b). The compounds (IIIa-b) were obtained by 
the reaction of (IIa-b) with hydrazine hydrate. Upon fusion 
of (IIIa-b) with 4-fluoro phenyl afforded the (IVa-b). The 
reaction of compounds (IVa-b) with thioglycolic acid gave 
(Va-b). The desired compounds (VIa-n) were obtained by 
refluxing the (Va-b) with various heteroaryl/ substituted 
aldehydes in 1,4 dioxane by adding few drops of glacial 
acetic acid. The target compounds were obtained in 54-71% 
yields (Table: 1).
Table: 1 Physical data of the synthesized compounds
Sl. 
No.
Compound 
code R Aryl Mol. Formula Mol. Wt. % Yield Rf M. P. (
oC)
1 VIa CH3 2-Furan C36H25FN4O4S 628.67 58 0.51 226-230
2 VIb CH3 2-Thiophene C36H25FN4O3S2 644.74 67 0.67 208-212
3 VIc CH3 3-Pyridine C37H26FN5O3S 639.70 54 0.35 222-228
4 VId CH3 4-Fluoro phenyl C38H26F2N4O3S 656.70 71 0.74 230-234
5 VIe CH3 2-Chloro phenyl C38H26ClFN4O3S 673.15 69 0.61 202-206
6 VIf CH3 4-Chloro phenyl C38H26ClFN4O3S 673.15 62 0.53 194-198
7 VIg CH3 4-Methoxy phenyl C39H29FN4O4S 668.74 60 0.47 190-194
8 VIh Cl 2-Furan C35H22ClFN4O4S 649.09 56 0.29 244-248
9 VIi Cl 2-Thiophene C35H22ClFN4O3S2 665.16 62 0.41 232-236
10 VIj Cl 3-Pyridine C36H23ClFN5O3S 660.12 56 0.52 240-244
11 VIk Cl 4-Fluoro phenyl C37H23ClF2N4O3S 677.12 69 0.36 248-252
12 VIl Cl 2-Chloro phenyl C37H23Cl2FN4O3S 693.60 63 0.68 226-230
13 VIm Cl 4-Chloro phenyl C37H23Cl2FN4O3S 693.60 61 0.46 218-222
14 VIn Cl 4-Methoxy phenyl C38H26ClFN4O4S 689.15 57 0.53 212-216
MTT assay
Cell viability was evaluated by the MTT Assay with three 
independent experiments with five concentrations of com-
pounds. MCF-7 and A549 cells were seeded in 96 well 
plates at a density of 5X103 cells/well. The cultures were 
treated with a series of concentration of 10-100 µg/ml of 
test and standard compounds and incubated at 37oC for 48 
hrs., followed by addition of MTT solution (5 mg/ml) to 
each plate and were incubated at 37oC for 3 hrs. At the end 
of incubation time, precipitates are formed as a result of the 
reduction of the MTT salt to chromophore formazan crys-
tals by the cells with metabolically active mitochondria. 
The optical density of solubilized crystals in DMSO was 
measured at 570 nm on a microplate reader15, 16. Percent-
age growth inhibition was calculated using the following 
formula. Results were indicated with mean and standard 
deviation (M±S.D.) of three independent experiments and 
were documented in Table: 2.
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Table: 2 Anticancer activity of synthesized compounds (VIa-n)
Sl. No. Compound R Aryl
IC50 (µM)
MCF-7 A549
1 Va CH3 ---- 0.053±0.003 0.065±0.002
2 Vb Cl ---- 0.048±0.004 0.055±0.002
3 VIa CH3 2-Furanyl 0.074±0.003 0.064±0.001
4 VIb CH3 2-Thiophenyl 0.116±0.002 0.140±0.002
5 VIc CH3 3-Pyridinyl 0.075±0.002 0.125±0.002
6 VId CH3 4-Fluorophenyl 0.066±0.003 0.035±0.002
7 VIe CH3 2-Chlorophenyl 0.093±0.002 0.135±0.002
8 VIf CH3 4-Chlorophenyl 0.079±0.003 0.123±0.002
9 VIg CH3 4-Methoxyphenyl 0.066±0.002 0.042±0.003
10 VIh Cl 2-Furanyl 0.063±0.002 0.040±0.003
11 VIi Cl 2-Thiophenyl 0.099±0.003 0.109±0.002
12 VIj Cl 3-Pyridinyl 0.065±0.003 0.092±0.002
13 VIk Cl 4-Fluorophenyl 0.054±0.003 0.031±0.003
14 VIl Cl 2-Chlorophenyl 0.075±0.002 0.106±0.002
15 VIm Cl 4-Chlorophenyl 0.066±0.002 0.093±0.002
16 VIn Cl 4-Methoxyphenyl 0.055±0.002 0.030±0.002
17 Standard --- --- 0.028±0.002 0.023±0.002
Standard: Doxorubicin
DISCUSSION 
Structures of synthesized compounds were ascertained by 
IR, NMR and Mass spectral studies. Elemental analysis re-
sults were in good agreement (±0.4%) with the calculated 
values. The mass spectra ESI-MS showed molecular ion 
peak at M+ corresponding to exact molecular weight of 
the respective compound. The IR spectral data of quinazo-
lin-4(3H)-one-thiazolidinone derivatives (VIa-n) showed 
characteristic absorption bands. The vibration frequencies 
of N-H stretching were found in the range of 3386-3278 
cm-1; C=O stretching bands were observed in the range of 
1729-1707 cm-1 and 1686–1644 cm-1 whereas C-F stretching 
at 1241-1164 cm-1. The 1H-NMR spectra of all compounds 
showed a singlet in the range of δ 9.28 – 9.09 ppm corre-
sponding to amide (–CO-NH–) proton. The proton of 
thiazolidinone-5-arylidene substitution (–C=CH–Ar-) ap-
peared as singlet between δ 8.95– 8.76 ppm; whereas thi-
azolidinone ring (–N-CH-S–) proton appeared as singlet 
between δ 5.91–5.79 ppm. The substituents of phenyl rings 
-CH3 (VIa-g) and -OCH3 (VIg & VIn) appeared as singlet 
signals between δ 2.38-2.18 ppm and δ 3.90-3.92 ppm re-
spectively. 13C-NMR spectra of VIa-n showed signals at 
frequencies in the range of δ 167-158 ppm associated with 
C=O of quinazolinone, thiazolidinone and amide. Further, 
the aliphatic carbons of CH3 and OCH3 appeared at δ ~20 
ppm and δ ~57 ppm respectively. All the other carbons of 
aromatic and hetero aromatic rings were observed in the 
region at δ 110-165 ppm.
Anticancer evaluation
The results revealed that all the tested compounds exhibit-
ed moderate to excellent activity against MCF-7and A549 
cell lines. The compounds Va and Vb with methyl and 
chloro substitution exhibited the highest potency against 
both the cell lines greater than that of their correspond-
ing arylidene derivatives (VIa-n). Compound Vb showed 
IC50 of 0.048±0.004 μM and 0.055±0.002 μM against MCF-
7 and A549 cell lines respectively compared to the IC50 
of 0.027±0.002 μM and 0.023±0.002 μM exhibited by the 
standard doxorubicin. Among the arylidene derivatives 
compound VIk (R = Cl; Ar = 4-F-C6H4), VIn (R = Cl; Ar = 
4-OCH3-C6H4) and VId (R = CH3; Ar = 4-F-C6H4) showed 
significant activity with IC50 values 0.031±0.003 μM, 
0.030±0.002 μM and 0.035±0.002 μM respectively against 
A549 cell lines, as compared to 0.023±0.002 μM showed by 
the standard doxorubicin. In addition, the arylidene de-
rivatives VIk and VIn also showed high potency against 
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MCF-7 cell lines with IC50 values 0.054±0.003 μM and 
0.055±0.002 μM respectively. Among the arylidene deriv-
atives, the compounds with 4-fluorophenyl substitution 
on C5 position of 4-thiazolidinone (VId & VIk) showed 
greater potency against both cell lines than the other with 
aryl and hetero aryl substitutions. The anticancer activity of 
synthesized derivatives and inhibition of growth of cell by 
VIk were depicted in Figure 2.
Molecular docking study
The lowest energy docked conformation of the ligands 
VIb, VIl and VIn revealed that the compounds bind with 
an overall binding energy of -62.964 kcal/mol, -81.968 
kcal/mol, -65.086 kcal/mol making intimate contacts with 
the residues of active site of the target enzyme phospho-
inositide-3-OH kinase (PI(3)K) through significant bonded 
and non-bonded interactions with higher docking scores 
-74.602, -99.037 and -76.787 respectively (Table 3). The 
ligand VIl showed three hydrogen bonding interaction 
with His-716, Arg-720, Lys-712 with high docking score 
(Figure: 3), whereas the ligand VIb with least anticancer 
activity showed three H-bond interactions with Arg-720, 
His-716. The ligand VIn which showed high potency also 
showed one hydrogen bond interaction with Arg-720. The 
compounds VIk and Vd, which exhibited highest activity 
against A549 cell lines and MCF-7 cell lines showed least 
docking scores, indicating that the cytotoxicity of the most 
active compound may due to other mechanism than the in-
hibition of PI(3)K enzyme.
 
Figure 2: (A) Comparing the IC50 (µM) of all synthesized com-
pounds and (STD) on the MCF-7 and A549 cells. The data repre-
sented as mean±S.D. (B) Dose dependant inhibition of MCF-7 and 
A549 cells by compound VIk, representing the images of one out 
of three experiments 
Table: 3 Molecular docking results: molecular docking scores, docking energies and H- bond interactions & distances of compounds 
with target PI(3)K (PDB ID: 2WXQ)
Sl. No. Compound Docking score Re-rank score Binding energy H-Bond & Distance
1 Va -25.527 -21.056 -14.382 -----
2 Vb -19.88 -13.748 -5.943 -----
3 VIa -47.131 -35.503 -41.105 -----
4 VIb -74.602 -57.884 -62.964 Arg 720; N(7)-6=3.44Å; 
His 716; N(7)-6=3.48Å & N(7)-9=3.58Å
5 VIc -16.32 0.068 -14.902 -----
6 VId -25.525 -19.874 -13.936 -----
7 VIe -38.777 -32.843 -22.84 -----
8 VIf -25.533 -20.745 -14.051 -----
9 VIg -73.171 -61.666 -59.036 Glu 713; N(7)-24=2.60Å 
Gln 710; N(7)-6=3.45Å
10 VIh -51.067 -43.871 -36.627 -----
11 VIi -25.807 -18.079 -15.17 -----
12 VIj -56.474 -47.974 -41.384 -----
13 VIk -20.918 -15.237 -9.425 -----
14 VIl -99.037 -60.212 -81.968
His 716; O(8)-10=2.60Å
Arg 720; O(8)-10=3.30Å
Lys 712; N(7)-27=2.90Å
15 VIm -20.918 -17.458 -13.87 -----
16 VIn -76.787 -62.39 -65.086 Arg 720; N(7)-6=3.44Å
130 Ars Pharm. 2018; 59(3): 121-131
Sukanya Nara, Achaiah Garlapati
Figure 3:(A) Docking orientation of compound VIl with the target enzyme (B) Compound VIl forming H-Bond interactions 
with amino acid residues of the target enzyme PI(3)K 
CONCLUSIONS
The present study revealed a new series of N-(2-(4-fluoro 
phenyl)-4-oxothiazolidin-3-yl)-4-(4-oxo-2-[(4-substituted 
phenyl)-quinazolin-3(4H)-yl)] benzamide derivatives were 
successfully synthesized and analyzed by various spectral 
methods. All the purified compounds were screened for 
their in vitro anti-cancer activity against MCF-7 and A549 
cell lines. Compounds Va, Vb, VId, VIh, VIk and VIn ex-
hibited potent anticancer activity with IC50 range of 0.030-
0.070 µM against MCF-7 and A549 cell lines. Docking re-
sults indicate that anticancer activity of the title compounds 
is not due to inhibition of PI(3)K enzyme.
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